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Screening of an FDA-Approved Compound Library Identifies Four
Small-Molecule Inhibitors of Middle East Respiratory Syndrome
Coronavirus Replication in Cell Culture
Adriaan H. de Wilde,a Dirk Jochmans,b Clara C. Posthuma,a Jessika C. Zevenhoven-Dobbe,a Stefan van Nieuwkoop,c
Theo M. Bestebroer,c Bernadette G. van den Hoogen,c Johan Neyts,b Eric J. Snijdera
Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, Netherlandsa; Rega Institute for Medical Research, KU,
Leuven, Belgiumb; Department of Viroscience, Erasmus Medical Center, Rotterdam, Netherlandsc
Coronaviruses can cause respiratory and enteric disease in a wide variety of human and animal hosts. The 2003 outbreak of se-
vere acute respiratory syndrome (SARS) first demonstrated the potentially lethal consequences of zoonotic coronavirus infec-
tions in humans. In 2012, a similar previously unknown coronavirus emerged, Middle East respiratory syndrome coronavirus
(MERS-CoV), thus far causing over 650 laboratory-confirmed infections, with an unexplained steep rise in the number of cases
being recorded over recent months. The humanMERS fatality rate of30% is alarmingly high, even thoughmany deaths were
associated with underlying medical conditions. Registered therapeutics for the treatment of coronavirus infections are not avail-
able. Moreover, the pace of drug development and registration for human use is generally incompatible with strategies to com-
bat emerging infectious diseases. Therefore, we have screened a library of 348 FDA-approved drugs for anti-MERS-CoV activity
in cell culture. If such compounds proved sufficiently potent, their efficacy might be directly assessed inMERS patients. We iden-
tified four compounds (chloroquine, chlorpromazine, loperamide, and lopinavir) inhibitingMERS-CoV replication in the low-
micromolar range (50% effective concentrations [EC50s], 3 to 8M). Moreover, these compounds also inhibit the replication of
SARS coronavirus and human coronavirus 229E. Although their protective activity (alone or in combination) remains to be as-
sessed in animal models, our findings may offer a starting point for treatment of patients infected with zoonotic coronaviruses
like MERS-CoV. Although they may not necessarily reduce viral replication to very low levels, a moderate viral load reduction
may create a window during which to mount a protective immune response.
In June 2012, a previously unknown coronavirus was isolatedfromapatientwho died fromacute pneumonia and renal failure
in Saudi Arabia (1, 2). Since then, the virus, now known as the
Middle East respiratory syndrome coronavirus (MERS-CoV) (3),
has been contracted by hundreds of others in geographically dis-
tinct locations in the Middle East, and evidence for limited hu-
man-to-human transmission has accumulated (4). Travel-related
MERS-CoV infectionswere reported froma variety of countries in
Europe, Africa, Asia, and the United States, causing small local
infection clusters in several cases (http://www.who.int/csr/disease
/coronavirus_infections/en/). About 200 laboratory-confirmed
humanMERS cases were registered during the first 2 years of this
outbreak, but recently, for reasons that are poorly understood
thus far, this number has more than tripled within just 2 months’
time (April-May 2014 [5]). This sharp increase in reported infec-
tions has enhanced concerns that we might be confronted with a
repeat of the 2003 severe acute respiratory syndrome (SARS) ep-
isode, concerns aggravated by the fact that the animal reservoir for
MERS-CoV remains to be identified with certainty (6–9). Fur-
thermore, at about 30%, the current human case fatality rate is
alarmingly high, even though many deaths were associated with
underlying medical conditions. MERS-CoV infection in humans
can cause clinical symptoms resembling SARS, such as high fever
and acute pneumonia, although the two viruses were reported to
use different entry receptors, dipeptidyl peptidase 4 (DPP4) (10)
and angiotensin-converting enzyme 2 (ACE2) (11), respectively.
Coronaviruses are currently divided across four genera:Alpha-
coronavirus, Betacoronavirus, Gammacoronavirus, and Deltacoro-
navirus (12). MERS-CoV was identified as a member of lineage C
of the genus Betacoronavirus (2), which also includes coronavi-
ruses of bat (13, 14) and hedgehog (6) origin. Following the 2003
SARS epidemic, studies into the complex genome, proteome, and
replication cycle of coronaviruses were intensified. Coronaviruses
are enveloped viruses with a positive-sense RNA genome of un-
precedented length (25 to 32 kb [12, 15, 16]). The crystal struc-
tures of a substantial number of viral nonstructural and structural
proteins were solved, and targeted drug design was performed for
some of those (reviewed in reference 17). Unfortunately, thus far,
none of these efforts resulted in antiviral drugs that were advanced
beyond the preclinical phase (18). The 2003 SARS-CoV epidemic
was controlled within a fewmonths after its onset, and since then,
the virus has not reemerged, although close relatives continue to
circulate in bat species (14). Consequently, the interest in anti-
coronavirus drug development has been limited, until the emer-
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gence of MERS-CoV. Despite the modest size of this CoV out-
break thus far, the lack of effective methods to prevent or treat
coronavirus infections in humans is a serious concern for the con-
trol of MERS-CoV or the next zoonotic coronavirus.
Antiviral research in the post-SARS era resulted in the identi-
fication of several compounds that may target coronavirus repli-
cation directly or modulate the immune response to coronavirus
infection. For example, entry inhibitors targeting the coronavirus
spike protein were developed (reviewed in reference 19). In addi-
tion, several of the replicative enzymes (including both proteases
and the helicase) were targeted with small-molecule inhibitors,
some of which can inhibit coronavirus infection in cell culture at
low-micromolar concentrations (20–26; reviewed in reference
27). Broad-spectrumantiviral agents, like the nucleoside analogue
ribavirin and interferon (IFN), were tested for their ability to in-
hibit SARS-CoV infection and were—to a limited extent—used
for the treatment of SARS patients during the outbreak (reviewed
in references 28 and 29). In the case of ribavirin, mixed results
were reported from studies in different cell lines, animal models,
and patients. Also, the merits of treating SARS patients with im-
munomodulatory corticosteroids have remained a matter of de-
bate (reviewed in references 28–30). ForMERS-CoV, partial riba-
virin sensitivity was observed in cell culture and in a macaque
animal model, but only when using very high doses of the com-
pound in combination with IFN-2b (31, 32). However, in a
small-scale clinical trial, this combination therapy did not benefit
critically illMERS patients (33). Nevertheless, the anticoronavirus
effects of type I IFN treatment deserve further evaluation, in par-
ticular since MERS-CoV seems to be considerably more sensitive
than SARS-CoV (34, 35). Treatment with type I IFNs inhibits
SARS-CoV andMERS-CoV replication in cell culture (31, 34–41)
and, for example, protected macaques against SARS-CoV (36) or
MERS-CoV (32) infection. Based on experiments in cell culture,
mycophenolic acid was recently reported to inhibit MERS-CoV
infection (41, 42), and we and others showed that low-micromo-
lar concentrations of cyclosporine inhibit coronavirus replication
(34, 43–45).
We recently described (34) a high-throughput assay for antivi-
ral compound screening that is based on the pronounced cyto-
pathic effect (CPE) caused by MERS-CoV infection in Vero and
Huh7 cells. This assaywas now further exploited to screen a library
of 348 FDA-approved drugs for their potential to inhibit MERS-
CoV replication. Chloroquine, chlorpromazine, loperamide, and
lopinavir were found to inhibit MERS-CoV replication in vitro at
low-micromolar concentrations. In addition, these molecules ap-
pear to be broad-spectrum coronavirus inhibitors, as they blocked
the replication of human coronavirus 229E and SARS-CoV with
comparable efficacy. Since these compounds have already been
approved for clinical use in humans, their anti-MERS-CoV activ-
ity merits further investigation, in particular in a small-animal
model for MERS-CoV infection, of which a first example has re-
cently been described (46).
MATERIALS AND METHODS
Cell culture and virus infection. Vero, Vero E6, and Huh7 cells were
cultured as described previously (34, 47). Infection ofVero andHuh7 cells
with MERS-CoV (strain EMC/2012 [1]) at high or low multiplicity of
infection (MOI) and SARS-CoV infection of Vero E6 cells (strain Frank-
furt-1 [48]) were done as described before (34). Infection with green
fluorescent protein (GFP)-expressing recombinant HCoV-229E (HCoV-
229E-GFP [49]) was performed in Dulbecco’s modified Eagle medium
(DMEM) containing 8% fetal calf serum (FCS), 2 mM L-glutamine (PAA
Laboratories), nonessential amino acids (PAA Laboratories), and antibi-
otics. HCoV-229E-GFP was used to infect monolayers of Huh7 cells at an
MOI of 5 as described previously (43). MERS-CoV and SARS-CoV titra-
tions by plaque assay were performed essentially as described before (50).
For titrations after high-MOI MERS-CoV infections (MOI of 1), cells
were washed twice with phosphate-buffered saline (PBS), and the virus
titer at 1 h postinfection (p.i.) was determined to correct for the remainder
of the inoculum. All work with live MERS-CoV and SARS-CoV was per-
formed inside biosafety cabinets in biosafety level 3 facilities at Leiden
UniversityMedical Center or ErasmusMedical Center, Rotterdam, Neth-
erlands.
Screening of an FDA-approved compound library. A library of 348
FDA-approved drugs was purchased from Selleck Chemicals (Houston,
TX, USA). Compounds were stored as 10mM stock solutions in dimethyl
sulfoxide (DMSO) at 4°C until use. Compound stocks were diluted to a
concentration of 200 or 60 M in Iscove’s modified Dulbecco’s medium
(Life Technologies) containing 1% FCS (PAA Laboratories) and antibiot-
ics. For MERS-CoV studies, Vero cells were seeded in 96-well plates at a
density of 2 104 cells per well. After overnight incubation of the cells at
37°C, each well was given 50 l of compound dilution, which was mixed
with 100l of Eagle’s minimal essential medium (EMEM) containing 2%
FCS (EMEM–2%FCS) and 50l ofMERS-CoV inoculum in EMEM–2%
FCS. The MOI used was 0.005, and the final compound concentrations
tested were 15 or 50 M. As a solvent control, a subset of wells was given
0.5%DMSO instead of compound dilution. At 3 days postinfection (dpi),
differences in cell viability caused by virus-induced CPE and/or com-
pound-specific side effects were analyzed using the CellTiter 96 AQueous
nonradioactive cell proliferation (monotetrazolium salt [MTS]) assay
(Promega), as described previously (34). The cytotoxic effects of com-
pound treatment were monitored in parallel plates containing mock-in-
fected cells, which were given regular medium instead of virus inoculum.
Compound validation. For validation experiments, we separately re-
ordered chlorpromazine (CPZ; S2456; SelleckChem), lopinavir (LPV;
ABT-378; SelleckChem), and loperamide (LPM; S2480; SelleckChem),
which were dissolved in DMSO, and chloroquine (CQ; C6628; Sigma)
which was dissolved in PBS. For all compounds, 20 mM stock solutions
were stored at 20°C as aliquots for single use. To verify the antiviral
effect of CQ, CPZ, LPM, and LPV on MERS-CoV replication, the assay
described above was repeated in 96-well plates using Huh7 cells (104 cells
seeded per well on the day before infection), and cell viability was assayed
at 2 dpi. Likewise, compounds were tested for their inhibitory effect on
SARS-CoV infection at 3 dpi (104 Vero E6 cells seeded per well; MOI,
0.005). For HCoV-229E-GFP infections, 104 Huh7 cells were seeded per
well, incubated overnight, and infected at anMOI of 5. Medium contain-
ing 0 to 50 M compound was given 1 h before the start of infection (t
1), and the compound remained present during infection.HCoV-229E-
GFP-infected Huh7 cells were fixed at 24 h p.i., and GFP expression was
quantified by fluorometry, as described previously (43).
Statistical analysis. The 50% effective concentration (EC50) and the
compound-specific toxicity (50% cytotoxic concentration [CC50]) were
calculatedwithGraphPad Prism 5 software using the nonlinear regression
model. The relative efficacy of a compound in specifically inhibiting viral
replication (as opposed to inducing cytopathic side effects) was defined as
the selectivity index (SI; calculated asCC50/EC50). Statistical analyses were
performed using the results of at least two independent experiments.
RESULTS
Screening for FDA-approved compoundswith anti-MERS-CoV
activity.Aprimary library screenwas performed using a set of 348
FDA-approved drugs that were evaluated for their ability to in-
hibit the replication of MERS-CoV in Vero cells (for a complete
list of compounds tested, see Dataset S1 in the supplemental ma-
terial) according to a recently published method that employs a
de Wilde et al.
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colorimetric cell viability assay to quantify virus-induced CPE
(34).
The primary screen resulted in the identification of 11 hits that
showed at least 50% inhibition of virus-induced CPE in the ab-
sence of cytotoxicity (which was defined as 75% viability in
compound-treated mock-infected cultures). Next, these drugs, as
well as the earlier reported coronavirus inhibitor chloroquine
(51–55), were tested over a broader concentration range (2 to 62.5
M; see Fig. S1 in the supplemental material). In this screen,
compounds were considered confirmed hits when they inhibited
MERS-CoV-induced CPE by 60% at nontoxic concentrations
(defined as75% remaining viability in compound-treated mock-
infected cultures). Following this second round of testing, cilnid-
ipine, fluoxetine HCl, ivermectin, manidipine, oxybutynin, pyri-
methamine, rifabutin, and rifapentine were not further retained
(see Fig. S1 in the supplemental material).
Low-micromolar concentrations of chloroquine, chlor-
promazine, loperamide, and lopinavir inhibit MERS-CoV rep-
lication. Four compounds were selected for further validation.
Chloroquine (CQ)was found to inhibitMERS-CoV replication in
a dose-dependent manner with an EC50 of 3.0 M (SI, 19.4; Fig.
1A andTable 1). Interestingly, another reported inhibitor of clath-
rin-mediated endocytosis (56), chlorpromazine (CPZ), was also
found to inhibit MERS-CoV-induced CPE (EC50, 4.9M; SI, 4.3)
with a 12 M dose achieving complete inhibition (Fig. 1B and
Table 1). Loperamide (LPM), an antidiarrheal agent, inhibited
FIG 1 Low-micromolar amounts of chloroquine, chlorpromazine, loperamide, and lopinavir inhibit MERS-CoV-induced cytopathology. Huh7 cells in 96-well
plates were infected with MERS-CoV isolate EMC/2012 (MOI, 0.005) in the presence of 0 to 32 MCQ (A), 0 to 16 MCPZ (B), 0 to 8 M LPM (C), or 0 to
20MLPV (D). Cells were incubated for 2 days, and cell viability wasmonitored using anMTS assay. In addition, the potential toxicity of compound treatment
onlywasmonitored in parallelmock-infectedHuh7 cell cultures. Graphs show the results (averages and standard deviations [SD]) of a representative experiment
that was performed in quadruplicate. All experiments were repeated at least twice. For each compound, the calculated EC50, CC50, and SI values are given.
TABLE 1 Antiviral activity of chloroquine, chlorpromazine, loperamide, and lopinavir against MERS-CoV, SARS-CoV, and HCoV-229E-GFPa
Compound
MERS-CoV SARS-CoV HCoV-229E-GFP
EC50 (M) CC50 (M) SI EC50 (M) CC50 (M) SI EC50 (M) CC50 (M) SI
Chloroquine 3.0 (	 1.1) 58.1 (	 1.1) 19.4 4.1 (	 1.0) 128 31 3.3 (	 1.2) 50 15
Chlorpromazine 4.9 (	 1.2) 21.3 (	 1.0) 4.3 8.8 (	 1.0) 24.3 (	 1.1) 2.8 2.5 (	 1.0) 23.5 (	 1.0) 9.4
Loperamide 4.8 (	 1.5) 15.5 (	 1.0) 3.2 5.9 (	 1.1) 53.8 (	 1.7) 9.1 4.0 (	 1.1) 25.9 (	 1.0) 6.0
Lopinavir 8.0 (	 1.5) 24.4 (	 1.0) 3.1 17.1 (	 1.0) 32 2 6.6 (	 1.1) 37.6 (	 1.3) 5.7
a EC50 and CC50 values are means (	 SD) from a representative experiment (n 4) that was repeated at least twice. Antiviral activity was determined in Huh7 cells (for MERS-
CoV and HCoV-229E-GFP) or VeroE6 cells (for SARS-CoV). See the text for more details.
FDA-Approved Drugs Inhibiting MERS-CoV Replication
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MERS-CoV-induced CPE with an EC50 of 4.8 M (Fig. 1C and
Table 1) but proved relatively toxic in Huh7 cells. An SI of 3.2 was
calculated, and a maximum of 82% inhibition was observed at 8
M, a concentration that was not cytotoxic. The fourth hit was the
human immunodeficiency virus type 1 (HIV-1) protease inhibi-
tor lopinavir (LPV), which was previously shown to inhibit SARS-
CoV main protease activity and SARS-CoV replication in vitro
(24). LPV inhibitedMERS-CoV-induced CPE with an EC50 of 8.0
M (SI, 3.1; Fig. 1D and Table 1), and a maximal protective effect
(89% inhibition) was observed at a dose of 12 M. Two other
MERS-CoV isolates (MERS-HCoV/KSA/UK/Eng-2/2012 and
MERS-HCoV/Qatar/UK/Eng-1/2012) (57) were found to be
equally sensitive to CQ, CPZ, and LPMwhile being somewhat less
sensitive to treatment with LPV (data not shown).
CQ, CPZ, LPV, and LPM also inhibit replication of SARS-
CoV and HCoV-229E. To investigate whether the MERS-CoV
inhibitors identified above are potential broad-spectrum corona-
virus inhibitors, we assessed their activity against two other coro-
naviruses: the alphacoronavirus HCoV-229E and the lineage B
betacoronavirus SARS-CoV (MERS-CoV belongs to lineage C).
All four compounds inhibited SARS-CoV-inducedCPE in a dose-
dependent manner (Fig. 2 and Table 1). For CQ, an EC50 of 4.1
M was observed (Fig. 2A), which is in line with earlier reports
(51, 52). This compound did not affect themetabolism of Vero E6
cells or induce alterations in cell morphology at concentrations of
up to 128M (CC50,128M; SI,31). LPM and CPZ blocked
SARS-CoV CPE with comparable EC50s (4.8 versus 4.9 M [Fig.
2B and C]). LPV completely blocked SARS-CoV-induced CPE at
12 M, with an EC50 of 8.0 M (Fig. 2D).
Anti-HCoV-229E activity was assessed employing a GFP-ex-
pressing recombinant virus, as described previously (43, 49). All
four compounds inhibited HCoV-229E-GFP replication at con-
centrations comparable to those needed to inhibit MERS-CoV
and SARS-CoV replication (Fig. 3 and Table 1). The CQ EC50 of
3.3 M (SI,15) for HCoV-229E-GFP was in the same range as
the previously reported concentration (10 M) needed to signif-
icantly reduce HCoV-229E production in the human cell line
L132 (53). Furthermore, CPZ, LPM, and LPV inhibited HCoV-
229E-GFP replication with EC50s of 2.5 M (SI, 9.4), 4.2 M (SI,
6.0), and 6.6 M (SI, 5.7), respectively.
Time-of-addition experiments suggest that CQ, CPZ, and
LPM inhibit an early step in the replicative cycle whereas LPV
inhibits a postentry step.BothCQ andCPZ are known inhibitors
of clathrin-mediated endocytosis and may thus inhibit MERS-
CoV infection at a very early stage. To investigate this, both com-
pounds were added to cells 1 h before (t1) or after (t
1)
infection (MOI, 1). Viral titers were determined at 24 h p.i. by
plaque assay (Fig. 4). Virus production was not affected by CQ
treatment when the compound was added at 1 h p.i. However,
when added prior to infection, 16 and 32 M concentrations of
FIG 2 Low-micromolar amounts of chloroquine, chlorpromazine, loperamide, and lopinavir inhibit SARS-CoV-induced cytopathology. Vero E6 cells in
96-well plates were infected with SARS-CoV isolate Frankfurt-1 (MOI, 0.005) in the presence of 0 to 32 MCQ (A), 0 to 16 MCPZ (B), 0 to 32 MLPM (C),
or 0 to 32 MLPV (D), given at t of
1 h p.i. Cells were incubated for 3 days, and viability was monitored using anMTS assay. In parallel, potential compound
cytotoxicity was monitored in mock-infected Vero E6 cells. Graphs show the results (averages and SD) of a representative experiment that was performed in
quadruplicate. All experiments were repeated at least twice. For each compound, the EC50, CC50, and SI values are given.
de Wilde et al.
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CQ induced an 1-log and 2-log reduction in virus production,
respectively (Fig. 4A). Comparable results were obtained upon
CQ treatment of MERS-CoV-infected Huh7 cells (Fig. 4B). The
results were less unambiguous for CPZ: addition 1 h prior to in-
fection led to an 2-log reduction of virus progeny titers; how-
ever, when added at 1 h p.i., a modest effect (0.5- to 1-log reduc-
tion)was observed (Fig. 4C andD), suggesting that the compound
may also affect MERS-CoV infection at a postentry stage. Treat-
ment with 16 MLPM in Vero cells reduced virus production by
2 log when added prior to infection, while a 1-log reduction was
observed when LPMwas added at 1 h p.i. (Fig. 4E). Although this
suggests a more pronounced effect early in MERS-CoV replica-
tion, this difference was not clearly observed when using Huh7
(compare Fig. 4E and F). Treatment with LPV from t of1 or
1
h p.i. was equally effective in inhibiting MERS-CoV progeny pro-
duction (2- to 3-log reduction), suggesting that LPV blocks a
postentry step in the MERS-CoV replicative cycle (Fig. 4G to H).
DISCUSSION
The ongoingMERS-CoV outbreak hasmade it painfully clear that
our current options for treatment of life-threatening zoonotic
coronavirus infections in humans are very limited. At present, no
drug is available for the treatment of any of the human or zoonotic
coronaviruses (reviewed in reference 58), despite the extensive
research efforts triggered by the 2003 SARS outbreak (reviewed in
references 26 and 27). The brevity of that epidemic is a major
reason why, thus far, none of the prototypic coronavirus inhibi-
tors was advanced beyond the (early) preclinical stage. Like SARS-
CoV a decade ago and MERS-CoV at present, future emerging
coronaviruses will likely continue to pose a threat to global public
FIG 3 HCoV-229E-GFP replication is inhibited by low-micromolar amounts of chloroquine, chlorpromazine, loperamide, and lopinavir. Huh7 cells in 96-well
plates were infected with HCoV-229E-GFP (MOI, 5) in the presence of 0 to 50 MCQ (A), CPZ (B), LPM (C), or LPV (D). Compounds were given at t of1
and remained present during infection. Cells were fixed at 24 h p.i., and GFP reporter gene expression wasmeasured and normalized to the signal in control cells
(100%; black bars), which were treated with the solvent used for the various compounds. The effect of compound treatment on the viability of mock-infected
Huh7 cells, compared with solvent-treated control cells, was determined by using an MTS assay (gray lines). Graphs show the results (average and SD) of a
representative quadruplicate experiment. All experiments were repeated at least twice; n.d., not detected.
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health. Therefore, the search for broad-spectrum inhibitors that
may reduce the impact of coronavirus infections in humans re-
mains a challenging research priority. Given the time-consuming
nature of antiviral drug development and registration, existing
therapeutics for other conditions may constitute the only imme-
diate treatment option in the case of emerging infectious diseases.
For most of these drugs, ample experience is available with dosing
in humans, and their safety and absorption, distribution, metab-
olism, and excretion (ADME) profiles are well known.
At the time of this study, a MERS-CoV infection model in
(small) animals was not available. For initial antiviral testing, we
therefore used our cell culture-based screening assay (34) to
search for compounds that may inhibit MERS-CoV infection.We
identified four FDA-approved compounds (chloroquine, chlor-
promazine, loperamide, and lopinavir) that inhibit the in vitro
replication of MERS-CoV at low-micromolar concentrations
(Fig. 1 and Table 1). While for some of these molecules the SI was
limited (10), for each of them we established at least one con-
centration at whichMERS-CoV replicationwas inhibited bymore
than 80%without a detectable reduction of cell viability. The same
four drugs were also found to inhibit, with comparable potency,
the in vitro replication of two other coronaviruses, i.e., HCoV-
229E and SARS-CoV (Fig. 2 and 3 and Table 1).
CQ inhibited MERS-CoV replication with an EC50 of 3.0 M
(Fig. 1A) andblocked infection at an early step (Fig. 4A andB). CQ
has a tendency to accumulate in lysosomes, where it sequesters
protons and increases the pH. In addition, it interacts with many
different proteins and cellular processes, resulting in the modula-
tion of autophagy and the immune response (for a review, see
reference 59). CQ has also been reported to inhibit the replication
of multiple flaviviruses, influenza viruses, HIV (reviewed in refer-
ence 60), Ebola virus (61), andNipah-Hendra virus (62), as well as
several coronaviruses, including SARS-CoV, in cell culture (51–
55, 63, 64). Early reports showed that high doses of CQ inhibit an
early step of the replication of the coronavirus mouse hepatitis
virus (MHV).However, in SARS-CoV-infected BALB/cmice, sys-
temically administered CQdid not result in a significant viral load
reduction in the lungs. Intranasal administration of CQ (50mg/kg
of body weight) resulted in a minor reduction of viral titers in the
lung (65). When pregnant mice were treated with CQ (at 15 mg/
kg), their newborn offspring were protected against a lethal chal-
lenge with HCoV-OC43 (54). Likely, the accumulation of CQ in
themilk glands, resulting in high drug concentrations inmaternal
milk, was a major factor in reaching a sufficiently high concentra-
tion of the drug in blood plasma. CQwas also shown to inhibit the
in vitro replication (EC50, 2 M) of the feline coronavirus infec-
tious peritonitis virus (FIPV) (55). Treatment of naturally in-
fected cats with CQ resulted in a clinical improvement, whichwas,
however, not attributed to a direct antiviral effect but likely due to
the immunomodulatory properties of CQ. These results highlight
that, e.g., the drug delivery route, virus strain used, and drug dos-
age might influence the outcome in animal models. In BALB/c
mice, steady-state concentrations of 8 M in plasma were ob-
served following repeated administration of CQ at 90 mg/kg (61),
which is above the EC50 of CQ for inhibition of MERS-CoV-in-
duced CPE in this study. Levels of 9 M in plasma were observed
FIG 4 Chloroquine, chlorpromazine, loperamide, and lopinavir affect various stages of the MERS-CoV replication cycle. Vero (A, C, E, G) and Huh7 cells (B,
D, F, H) were infected with MERS-CoV isolate EMC/2012 (MOI, 1). At t of1 or
1, the indicated concentrations of CQ (A, B), CPZ (C, D), LPM (E, F), and
LPV (G, H) were added, and virus titers in the culture supernatant (n 4; averages and SDs are shown) were determined at 24 h p.i. using plaque assays; n.d.,
not detected.
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in humans following CQ treatment with 8 mg/kg/day for three
consecutive days (66).
The second FDA-approved drug found to block MERS-CoV
infection was CPZ, the first antipsychotic drug developed for
treatment of schizophrenia (67). CPZ affects the assembly of
clathrin-coated pits at the plasma membrane (56) and has been
reported to inhibit the replication of alphaviruses (68), hepatitis C
virus (69), and the coronaviruses SARS-CoV (70), infectious
bronchitis virus (71), and MHV-2 (72). Our time-of-addition
studies, however, suggest that CPZ inhibits MERS-CoV replica-
tion at both an early and a postentry stage, implying that an effect
on clathrin-mediated endocytosis is unlikely to be the sole antivi-
ral mechanism (Fig. 4C and D). CPZ plasma concentrations in
patients treated for psychotic disorders range between 0.3 and 3
M (73), which is somewhat below the observed EC50s observed
here (which range between 2 and 9 M).
The replication of MERS-CoV in vitro was also inhibited by
LPM, an antidiarrheal opioid receptor agonist that reduces intes-
tinal motility (reviewed in reference 74). LPM also inhibits the
replication of two other coronaviruses at low-micromolar con-
centrations (4 to 6 M). Upon oral or intravenous administra-
tion, the molecule rapidly concentrates in the small intestine. Less
than 1% of orally taken LPM is absorbed from the gut lumen, and
its tendency to concentrate at the site of action is the probable
basis for its antidiarrheal effect (75). This property would very
much limit systemic use for the treatment of respiratory corona-
virus infections, although administration in the formof an aerosol
might be explored. In the veterinary field, it would be interesting
to test whether the compound has the potential to inhibit enteric
coronaviruses, such as the porcine transmissible gastroenteritis
coronavirus.
Finally, the HIV-1 protease inhibitor (PI) LPV was shown to
inhibitMERS-CoV replicationwith EC50s of about 8M,which is
in the range of the LPV concentrations in plasma (8 to 24M) that
have been observed in AIDS patients (76). LPV was previously
shown to block the SARS-CoV main protease (Mpro) (24). This is
somehow unexpected, since the retro- and coronavirus proteases
belong to different protease families (the aspartic and chymotryp-
sin-like protease families, respectively). Since MERS-CoV and
SARS-CoV are relatively closely related, LPV may also target the
Mpro of MERS-CoV. However, several anti-HIV PIs are also
known to influence intracellular pathways leading to side effects in
patients undergoing highly active antiretroviral therapy, includ-
ing lipodystrophy and insulin resistance (77). The exact cellular
targets of these PIs have not yet been identified, and most likely
multiple pathways are involved. It remains to be investigated if the
effect of LPV on these intracellular pathways is associated with the
anti-CoV activity found here. Interestingly, no selective anti-CoV
activity was found for two other HIV PIs in the compound library
(atazanavir and ritonavir; see Dataset S1 in the supplemental ma-
terial). During the SARS outbreak, treatment with LPV, in com-
bination with ritonavir, was explored with some success in non-
randomized clinical trials (for reviews, see references 78 and 79).
The efficacy of the most promising compounds identified in
this study, CQ and LPV, should now be evaluated in (small-)
animal models for MERS-CoV infection, which are still in devel-
opment. In a nonhuman primate model (macaques), only mild
clinical signs developed, in contrast to the frequently severe clin-
ical outcome in humans (80, 81). Unfortunately, Syrian hamsters
(82), BALB/c mice (83), and ferrets (84) were found to resist
MERS-CoV infection. A very recent study (46) reported that mice
can be rendered susceptible to MERS-CoV infection by prior
transduction with a recombinant adenovirus that expresses hu-
man DPP4, a documented receptor for MERS-CoV entry (10).
Subsequent MERS-CoV infection resulted in severe pneumonia
and high MERS-CoV titers in the lungs (46). Despite some prac-
tical and conceptual limitations, this model may provide a useful
starting point for further evaluation of inhibitors of MERS-CoV
infection.
In 2003, the 10% mortality rate among SARS patients was
one of the major reasons for the worldwide public unrest caused
by the emergence of SARS-CoV. Clearly, and despite the recent
sharp increase in the number of registered cases (5), the course of
the MERS-CoV outbreak has been quite different thus far. Al-
though only about 650 laboratory-confirmed cases have been reg-
istered in the 2 years that have passed since the first documented
human infections, in particular the 30% mortality rate within
this group remains a grave concern. In this context, efficacious
anticoronavirus drugs, administered alone or in combination, can
constitute an important first line of defense. It typically takes over
10 years to develop a newly discovered molecule and obtain ap-
proval for clinical use. To the best of our knowledge, there are
currently no potent and selective coronavirus inhibitors in (early
or advanced) preclinical development. Hence, drugs that have
been registered for the treatment of other conditions and that also
inhibit MERS-CoV replication might be used (off-label) in an
attempt to save the life ofMERS patients. A combination of two or
more of such drugs may cause a modest reduction in viral load,
whichmight aid to control viral replication, slow down the course
of infection, and allow the immune system to mount a protective
response. In an accompanying paper by Dyall et al. (85), CQ and
CPZ were identified as inhibitors of the MERS-CoV as well. Fol-
low-up studies will include in-depthmechanism of action studies,
including resistance development ofMERS-CoV against the com-
pounds identified. Furthermore, the efficacy of combinations of
two or more of these drugs will be explored, also in combination
with interferon. In particular, CQ and LPV may constitute valu-
able candidates for further testing in animal models or direct off-
label use, since the concentrations needed to inhibit viral replica-
tion in cell culture are in the range of the concentrations that can
be achieved in human plasma.
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